Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losenatide for weight loss and safety in obese adults with type 2 diabetes
ChiCTR2000040391Phase 4Not yet recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Jan 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4 trial of loxenatide in type 2 diabetes mellitus (T2DM) and obesity (5 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoints: Analysis of human body composition, IWQOL-Lite quality of life and 3 more. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
loxenatide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on ChiCTR2000040391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040391.